相关实验视频

Updated: Jan 15, 2026

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

通过微轴流进行心脏移植的患者之间的结果与耐用左心室辅助器件支持的耐用左心室辅助器件相比

Alejandro Alvarez¹, Krish C Dewan¹, Carmelo A Milano¹

¹Division of Cardiothoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC.

The Journal of thoracic and cardiovascular surgery

|October 9, 2025

概括

心脏移植的微轴左心室辅助装置 (ma-LVAD) 桥梁显示了与持久性LVAD (d-LVAD) 相似的生存率. ma-LVAD使用与手术后并发症减少和住院时间缩短有关.

科学领域:

心脏病学心脏病学
移植手术移植手术
医疗器械医疗器械

背景情况:

整形心脏移植 (OHT) 需要有效的桥梁策略来治疗末期心力衰竭.
左心室辅助器件 (LVAD) 对于改善OHT等待患者的治疗结果至关重要.
评估不同的LVAD类型,如微轴LVAD (ma-LVAD) 和持久LVAD (d-LVAD),对于优化患者护理至关重要.

研究的目的:

为了比较使用ma-LVAD与d-LVAD桥接到OHT的患者的特征和结果.
评估两种桥梁策略之间的生存率和术后发病率.
分析ma-LVAD与d-LVAD对移植功能和患者康复的影响.

主要方法:

进行了一项单一中心的回顾性队列研究.
分析了从2019年5月到2024年5月接受OHT的患者数据.
用ma-LVAD结合的患者的特征和结果与用d-LVAD结合的患者进行了比较.

主要成果:

虽然基线特征相似,但与d-LVAD桥接的患者患高血压,BMI和HLA抗体的比率更高.
在ma-LVAD和d-LVAD桥梁策略之间没有观察到生存的显著差异.
与d-LVAD桥接的患者经历了明显更高的术后血液制品使用,初级移植功能障碍,延迟的胸关闭和排斥率.

结论:

ma-LVAD和d-LVAD显示了可比的生存率作为OHT的桥梁策略.
与ma-LVAD相结合,与d-LVAD相比,术后发病率显著降低.
ma-LVAD是一种可行的替代性桥梁策略,有可能改善移植后的恢复.

关键词:

这是一个心脏MateMate.伊姆佩拉 (Impella) 是一种.这就是VAD VAD.桥梁到移植的桥梁机械循环支持机械循环支持这是一个微轴的微轴.腹腔室辅助器件可以帮助心室.

更多相关视频

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

相关概念视频

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...